You-Quan Li1, An-Hui Shi, Fu-Hai Li, Rong Yu, Guang-Ying Zhu. 1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Radiation Oncology, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing 100142, China.
Abstract
OBJECTIVE: To evaluate the maximum tolerated dose (MTD) of docetaxel (DCT) and cisplatin (DDP) concurrently with three dimensional (3D) conformal radiotherapy or IMRT for patients with locally advanced non-small cell lung cancer (stage IIIa and IIIb) after 2-4 cycles of induction chemotherapy. METHODS: Fourteen patients with histological/cytological proven stage III non-small-cell lung cancer were eligible. 3D or IMRT radiotherapy (60-70Gy in 30-35 fractions, 6-7weeks, 2 Gy/fraction) was delivered concurrently with cisplatin and docetaxel, 2 cycles during concurrent chemoradiotherapy (CCRT). The level I dosage was composed of 56 mg/m(2) DCT, on day 1 and 28mg/m(2) DDP, on day 1 and day 2. The level II was composed of 60 mg/m(2) DCT, on day 1 and 30 mg/ m(2) DDP, on day 1 and day 2. The level III was composed of 64 mg/m(2) DCT, on day 1 and 32 mg/ m(2) DDP, on day 1 and day 2. RESULTS: Fourteen patients were allocated and finished concurrent chemoradiotherapy. The dose-limiting neutropenia was at the dose Level III (64 mg/m(2)) and occurred in 2 of 5 patients. No dose limiting non-hematologic or hematologic toxicity occurred in the other patients. CONCLUSIONS: Patients with locally advanced non-small cell lung cancer may tolerate 60mg/m(2) docetaxel and 60mg/m(2) cisplatin for 2 cycles during concurrent radiotherapy after 2-3 cycles of induction chemotherapy.
OBJECTIVE: To evaluate the maximum tolerated dose (MTD) of docetaxel (DCT) and cisplatin (DDP) concurrently with three dimensional (3D) conformal radiotherapy or IMRT for patients with locally advanced non-small cell lung cancer (stage IIIa and IIIb) after 2-4 cycles of induction chemotherapy. METHODS: Fourteen patients with histological/cytological proven stage III non-small-cell lung cancer were eligible. 3D or IMRT radiotherapy (60-70Gy in 30-35 fractions, 6-7weeks, 2 Gy/fraction) was delivered concurrently with cisplatin and docetaxel, 2 cycles during concurrent chemoradiotherapy (CCRT). The level I dosage was composed of 56 mg/m(2) DCT, on day 1 and 28mg/m(2) DDP, on day 1 and day 2. The level II was composed of 60 mg/m(2) DCT, on day 1 and 30 mg/ m(2) DDP, on day 1 and day 2. The level III was composed of 64 mg/m(2) DCT, on day 1 and 32 mg/ m(2) DDP, on day 1 and day 2. RESULTS: Fourteen patients were allocated and finished concurrent chemoradiotherapy. The dose-limiting neutropenia was at the dose Level III (64 mg/m(2)) and occurred in 2 of 5 patients. No dose limiting non-hematologic or hematologic toxicity occurred in the other patients. CONCLUSIONS:Patients with locally advanced non-small cell lung cancer may tolerate 60mg/m(2) docetaxel and 60mg/m(2) cisplatin for 2 cycles during concurrent radiotherapy after 2-3 cycles of induction chemotherapy.
Authors: T Le Chevalier; R Arriagada; M Tarayre; M J Lacombe-Terrier; A Laplanche; E Quoix; P Ruffie; M Martin; J Y Douillard Journal: J Natl Cancer Inst Date: 1992-01-01 Impact factor: 13.506
Authors: H Choy; R F DeVore; K R Hande; L L Porter; P A Rosenblatt; B Slovis; K Laporte; Y Shyr; D H Johnson Journal: Lung Cancer Date: 2001-12 Impact factor: 5.705
Authors: K Furuse; M Fukuoka; M Kawahara; H Nishikawa; Y Takada; S Kudoh; N Katagami; Y Ariyoshi Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: Raja Mudad; Maggie Ramsey; Kevin Kovitz; Tyler J Curiel; Renee Hartz; Lucien L Nedzi; Roy S Weiner; Ellen L Zakris Journal: Lung Cancer Date: 2003-02 Impact factor: 5.705
Authors: H Choy; W Akerley; H Safran; J Clark; V Rege; A Papa; M Glantz; Y Puthawala; C Soderberg; L Leone Journal: J Clin Oncol Date: 1994-12 Impact factor: 44.544
Authors: C Schaake-Koning; W van den Bogaert; O Dalesio; J Festen; J Hoogenhout; P van Houtte; A Kirkpatrick; M Koolen; B Maat; A Nijs Journal: N Engl J Med Date: 1992-02-20 Impact factor: 91.245